Experienced in Pseudobulbar Affect

Philippe Couratier

Limoges, FR 
Experienced in Pseudobulbar Affect
Limoges, FR 
OverviewLocationsClinical Research

Overview

Philippe Couratier practices in Limoges, France. Mr. Couratier is rated as an Experienced expert by MediFind in the treatment of Pseudobulbar Affect. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Dementia, Frontotemporal Dementia, and Gastrostomy.

His clinical research consists of co-authoring 153 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pseudobulbar Affect.

Gender
Male

Locations

Limoges, 87100, France
Other Locations
Tours, France
Clermont-ferrand, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
Enrollment Status: Active_not_recruiting
Publish Date: November 30, 2023
Intervention Type: Other
Study Phase: Not Applicable
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Unknown
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: Tauroursodexycholic Acid
Study Phase: Phase 3
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Enrollment Status: Completed
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drugs: Riluzole, IL-2
Study Phase: Phase 2
Impact on Functional Status of Early Oral Nutritional Supplementation (ONS) in Amyotrophic Lateral Sclerosis (ALS) Patients
Impact on Functional Status of Early Oral Nutritional Supplementation (ONS) in Amyotrophic Lateral Sclerosis (ALS) Patients
Enrollment Status: Completed
Publish Date: August 19, 2021
Intervention Type: Dietary supplement
Study Phase: Not Applicable
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Enrollment Status: Completed
Publish Date: July 17, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Enrollment Status: Completed
Publish Date: August 04, 2017
Intervention Type: Other, Drug, Radiation
View 5 Less Clinical Trials

153 Total Publications

Improving ALS Molecular Diagnosis Through Functional Assays: Reassessment of a SOD1 Variant of Uncertain Significance.
Improving ALS Molecular Diagnosis Through Functional Assays: Reassessment of a SOD1 Variant of Uncertain Significance.
Journal: International journal of molecular sciences
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Couratier's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile